Clinical Trial Update: A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating adverse events of Fosigotifator (ABBV-CLS-7262) in adults with major depressive disorder has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Fosigotifator (ABBV-CLS-7262)

Snippet

Sponsor: AbbVie | Conditions: Major Depressive Disorder (MDD) | Phase 1 | Status: TERMINATED